In a statement, Alexion Pharmaceuticals (NASDAQ:ALXN) says it has established a “strong foundation” to drive growth and boost shareholder value and does not plan to pursue an outright sale as proposed by shareholder Elliott Advisors.
Management cites it new leadership team, a refined strategy to convert the market to Ultomiris (ravulizumab-cwvz) from Soliris (eculizumab), the expansion of current assets into new diseases and a revamped pipeline.
Shares up 6% premarket on modest volume.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.